The stock of Quintiles IMS Holdings Inc (NYSE:Q) is a huge mover today! The stock decreased 5.07% or $4.1 during the last trading session, hitting $76.83. About 4.71M shares traded hands or 166.10% up from the average. Quintiles IMS Holdings Inc (NYSE:Q) has risen 15.91% since April 27, 2016 and is uptrending. It has outperformed by 10.69% the S&P500.
The move comes after 5 months negative chart setup for the $19.18 billion company. It was reported on Nov, 30 by Barchart.com. We have $74.53 PT which if reached, will make NYSE:Q worth $575.40 million less.
Analysts await Quintiles IMS Holdings Inc (NYSE:Q) to report earnings on February, 9. They expect $1.07 EPS, up 18.89% or $0.17 from last year’s $0.9 per share. Q’s profit will be $267.12M for 17.95 P/E if the $1.07 EPS becomes a reality. After $1.00 actual EPS reported by Quintiles IMS Holdings Inc for the previous quarter, Wall Street now forecasts 7.00% EPS growth.
Quintiles IMS Holdings Inc (NYSE:Q) Ratings Coverage
Out of 15 analysts covering Quintiles Transnational (NYSE:Q), 6 rate it a “Buy”, 0 “Sell”, while 9 “Hold”. This means 40% are positive. Quintiles Transnational has been the topic of 21 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, October 5 by Goldman Sachs. The rating was initiated by Avondale on Wednesday, October 21 with “Sector Weight”. The rating was downgraded by Evercore on Wednesday, May 4 to “Hold”. Zacks upgraded Quintiles IMS Holdings Inc (NYSE:Q) rating on Thursday, August 27. Zacks has “Hold” rating and $79 price target. The company was downgraded on Tuesday, August 25 by Zacks. The company was downgraded on Monday, March 28 by SunTrust. The company was maintained on Wednesday, October 5 by UBS. The stock of Quintiles IMS Holdings Inc (NYSE:Q) has “Buy” rating given on Friday, February 12 by Deutsche Bank. The company was downgraded on Thursday, October 27 by Piper Jaffray. As per Friday, September 4, the company rating was downgraded by Zacks.
According to Zacks Investment Research, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina.”
Insitutional Activity: The institutional sentiment decreased to 0.75 in Q2 2016. Its down 0.38, from 1.13 in 2016Q1. The ratio dropped, as 39 funds sold all Quintiles IMS Holdings Inc shares owned while 110 reduced positions. 54 funds bought stakes while 115 increased positions. They now own 108.59 million shares or 4.92% more from 103.49 million shares in 2016Q1.
Parametric Associates Ltd Llc has 206,834 shares for 0.02% of their US portfolio. Capstone Asset Mngmt holds 7,230 shares or 0.01% of its portfolio. Glenmede Trust Company Na reported 208,766 shares or 0.08% of all its holdings. First Mercantile Tru has 20,360 shares for 0.17% of their US portfolio. Natixis reported 56,761 shares or 0.07% of all its holdings. The New Jersey-based Jacobs Levy Equity Mngmt has invested 0.16% in Quintiles IMS Holdings Inc (NYSE:Q). Tfs Ltd Liability holds 0.07% or 5,476 shares in its portfolio. Beaconlight Capital Ltd Liability has 112,934 shares for 3.44% of their US portfolio. Westpac Bk Corp last reported 266,344 shares in the company. British Columbia Mgmt has 0.04% invested in the company for 68,219 shares. Andra Ap last reported 21,400 shares in the company. Guggenheim has invested 0.04% of its portfolio in Quintiles IMS Holdings Inc (NYSE:Q). Winslow Evans & Crocker Inc last reported 0% of its portfolio in the stock. Barclays Pcl holds 0.01% of its portfolio in Quintiles IMS Holdings Inc (NYSE:Q) for 100,201 shares. Rhumbline Advisers holds 0.02% of its portfolio in Quintiles IMS Holdings Inc (NYSE:Q) for 84,567 shares.
More recent Quintiles IMS Holdings Inc (NYSE:Q) news were published by: Streetinsider.com which released: “Form 8-K Quintiles IMS Holdings, For: Nov 29” on November 30, 2016. Also Streetinsider.com published the news titled: “Quintiles IMS Holdings (Q) Completes Merger of Equals Transaction Between IMS …” on October 03, 2016. Bloomberg.com‘s news article titled: “IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal” with publication date: May 03, 2016 was also an interesting one.
Q Company Profile
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., incorporated on November 19, 2009, is a well-known provider of biopharmaceutical development services and commercial outsourcing services. The Firm is engaged in the development and commercialization of pharmaceutical therapies. The Company’s divisions include Product Development and Integrated Healthcare Services. The Firm offers therapeutic, scientific and analytics services to its biopharmaceutical and other healthcare customers. The Company’s Product Development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company’s Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations. The Company’s Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.